Read by QxMD icon Read


Ting Shuang, Min Wang, Cong Shi, Yingying Zhou, Dandan Wang
MiR-134 has been reported to have a role in the development and progression of various cancers. In this study, we found that miR-134 expression was significantly decreased in chemo-resistant serous epithelial ovarian cancer (EOC) patients. Over-expression of miR-134 enhanced the sensitivity of SKOV3-TR30 cells to paclitaxel, and increased paclitaxel-induced apoptosis. Further, Pak2 was identified as a direct target of miR-134, and Pak2-specific siRNA increased cell inhibition rate and promoted paclitaxal-induced apoptosis...
October 7, 2015: FEBS Letters
Mingjie Zhou, Zhaohui Li, Ziwu Han, Nan Tian
Although paclitaxel is an effective chemotherapeutic drug used in the treatment of many tumors, hepatoma cells, in particular, are known to be highly resistant to it. Previously, we discovered that Lin28 was closely associated with resistance to paclitaxel in Hep3B cells. The nuclear factor-kappa B (NF-κB) transcription factor, which plays an important role in tumor survival, directly activates Lin28 expression through a binding site on the first intron. Curcumin, a non-toxic anti-inflammatory agent, inhibits NF-κB activity in vitro...
2015: Journal of Receptor and Signal Transduction Research
Akiko Okamoto, Katsuhiko Nakatsukasa, Yoshifumi Fujita, Riho Sugimoto, Kouichi Sakaguchi, Tetsuya Taguchi
Paclitaxel combined with bevacizumab yields significantly better progression-free survival (PFS) in patients with metastatic breast cancer than paclitaxel alone. Here, we report a case of stage IV breast cancer with multiple liver, lung, and bone metastases maintaining a long-term partial response (PR) with tri-weekly paclitaxel plus bevacizumab administration. A 46- year-old woman treated with endocrine therapy for 21 months for multiple metastases in her lungs and bones detected 4 years after surgery for left breast cancer was referred to our hospital...
March 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Upasana Baruah, Debabrata Barmon, Amal Chandra Kataki, Pankaj Deka, Munlima Hazarika, Bhargab J Saikia
CONTEXT: Patients with advanced ovarian cancer have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced ovarian cancer; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in patients with advanced ovarian cancer. AIMS: This study aims to evaluate the survival statistics of the patients who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009...
January 2015: Indian Journal of Medical and Paediatric Oncology
D J Chu, D E Yao, Y F Zhuang, Y Hong, X C Zhu, Z R Fang, J Yu, Z Y Yu
Although new chemotherapeutic drugs have been applied constantly, their efficacy for non-small cell lung cancer (NSCLC) is still not satisfactory. In recent years, epidemiological investigations have shown that lung cancer may be induced by chronic Chlamydia pneumoniae (Cpn) infection, since stable high titers of Cpn antibodies, especially IgA, are a hallmark of chronic infections. Azithromycin is commonly used for the treatment of Cpn infections; however, there are only few reports regarding the application of azithromycin (A) combined with paclitaxel and cisplatin (TP) for advanced NSCLC...
2014: Genetics and Molecular Research: GMR
Miau-Hwa Ko, Ming-E Hu, Yu-Lin Hsieh, Chyn-Tair Lan, To-Jung Tseng
Paclitaxel in chemotherapy-induced peripheral neuropathy (CIPN) is predominantly with a dose-limiting effect on neuropathic pain in clinical strategy. In the present study, the relationship between the neuropathic pain and nerve degeneration in paclitaxel CIPN was investigated. Adult male Sprague-Dawley (SD) rats were divided into three paclitaxel groups (0.5, 1.0, 2.0mg/kg) and a vehicle group with four intraperitoneal (i.p.) injections on alternating days. Our results demonstrated that the paclitaxel groups significantly exhibited the reductions of thermal hyperalgesia and mechanical allodynia...
June 2014: Neuropeptides
Ryo Kato, Kazuyuki Okada, Chikara Ebisui, Yuma Wada, Shunichiro Makino, Tomohira Takeoka, Tetsu Yanagisawa, Shu Okamura, Nariaki Fukuchi, Kouhei Murata, Hideoki Yokouchi, Masakatsu Kinuta
Herein, we report the case of 57-year-old woman who visited our hospital for abdominal distention, difficulty in walking, and edema of the legs in January 2012. She underwent gastroendoscopy, resulting in a diagnosis of advanced gastric cancer of the pyloric antrum. A diagnosis of unresectable advanced gastric cancer was made because computed tomography (CT) showed the presence of ascites (suspected to indicate peritoneal dissemination), para-aortic lymph node metastases, and brain metastases. Stenting was performed for pyloric stenosis and cell-free and concentrated ascites reinfusion therapy (CART) was administered to facilitate oral intake...
November 2013: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Katsuyuki Mayumi, Masanobu Terakura, Genya Hamano, Takashi Ikebe, Masashi Takemura, Takaaki Hori
A 74-year-old man who had undergone distal gastrectomy was diagnosed with metastasis to the spleen and transverse colon 27 months after the operation, and 6 courses of combination therapy with S-1 and cisplatin (CDDP) were administered. However, both lesions showed progressive disease (PD) after chemotherapy. Massive gastrointestinal hemorrhage from colon metastases was observed following the administration of irinotecan(CPT-11). Therefore, total remnant gastrectomy, splenectomy, and partial transverse colectomy were performed via the laparoscopic approach...
November 2013: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Junji Kawada, Masashige Nishimura, Yuki Matsui, Masatoshi Nomura, Yuki Noguchi, Yuichiro Okumura, Katsuki Danno, Masaru Kubota, Chu Matsuda, Kenichi Omori, Kazuhiro Nishikawa, Masaya Nomura, Mari Takagi, Akiko Fukui, Kazumasa Fujitani, Kazuhiro Iwase, Yasuhiro Tanaka
PURPOSE: Public knowledge-based application for paclitaxe(l PAC) has been approved for advanced or recurrent esophageal cancer. We investigated the feasibility of weekly PAC chemotherapy as a second-line or subsequent regimen for metastatic or recurrent esophageal cancer. MATERIALS AND METHODS: Patients received PAC( 100 mg/m2 intravenously) on days 1, 8, 15, 22, 29, and 36 of each 8-week period. We analyzed the toxicity and efficacy in 6 patients treated with the weekly PAC chemotherapy...
November 2013: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Lishan Wang, Weidong Zang, Dongli Xie, Weidong Ji, Yaosheng Pan, Zhiqiang Li, Jiawei Shen, Yongyong Shi
BACKGROUND: Drug-eluting stents (DES) are increasingly used for treatment of acute coronary syndrome (ACS). However, clinical efficacy and safety of various types of DES is not well established in these subjects. We therefore evaluated clinical utility of second-generation and first-generation DES in patients with ACS by conducting a meta-analysis. METHODS: A search of Medline, Embase, the Cochrane databases, and Web of Science was made. Randomized controlled trials (RCTs) which compared second-generation DES (everolimus-eluting stents [EES] or zotarolimus-eluting stents [ZES]) versus first-generation DES (sirolimus-eluting stents [SES] or paclitaxe-eluting stents [PES]) in patients with ACS and provided data on clinical efficacy or safety endpoints were included...
2013: PloS One
K Makwana, H Tandel
Despite its strong antitumor activity, paclitaxel (Taxol(®)) has limited clinical applications due to its low aqueous solubility and hypersensitivity caused by cremophor EL and ethanol which is the vehicle used in the current commercial product. In an attempt to develop a pharmaceutically acceptable formulation that could replace Taxol(®), we have prepared PEGylated liposomes containing paclitaxel to improve its solubility and physicochemical stability. Its percent drug entrapment (PDE), mean particle size, zeta potential and in vitro release profile were determined...
March 2012: Journal of Pharmacy & Bioallied Sciences
Shao-Liang Chen, Gary Mintz, Teguh Santoso, Jun-Jie Zhang, Fei Ye, Ya-Wei Xu, Qiang Fu, Jing Kan, Chitprapai Paiboon, Yong Zhou, Shi-Qin Ding, Tak W Kwan
BACKGROUND: The difference in clinical outcome between paclitaxal-eluting stents (PES) and sirolimus-eluting stents with bio-degradable polymer (SES-BDP) for bifurcation lesions remains unclear. The present study aimed to investigate the one-year clinical outcome after DK crush stenting using PES (Taxus(TM)) vs. SES-BDP (Excel(TM)) from our database. METHODS: A total of 275 patients (90 from the DKCRUSH-I and 185 from the DKCRUSH-II study) were studied. The primary endpoint was the occurrence of major adverse cardiac events (MACE) at 12 months; including cardiac death, myocardial infarction (MI), or target vessel revascularization (TVR)...
October 2012: Chinese Medical Journal
Kenji Okumura, Souichiro Tani, Youji Shiogai, Masashi Kodama, Eiji Mekata, Tohru Tan
We report two cases of advanced gastric cancer. The first was a 77-year-old man who had experienced distal gastrectomy about 35 years ago. He complained of abdominal bloating, and a gastrointestinal scope showed that he had advanced gastric cancer. CT scan revealed massive ascites. Dissemination of the peritoneum was suspected, and chemotherapy using S-1 (80mg/m², biweekly)plus paclitaxel (50mg/m², on days 1 and 8) was selected, He had no major side effects and the ascites disappeared. He was able to receive 18 courses on an outpatient basis...
April 2012: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Masaki Miyazaki, Katsuhiko Naoki, Takashi Sato, Kyuto Tanaka, Keishi Tsuzuki, Shuichi Yoshida, Katsuyoshi Tomomatsu, Sadatomo Tasaka, Kenzo Soejima, Koichi Sayama, Koichiro Asano
A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line(cisplatin+docetaxel→CPT-11+S-1→amrubicin→gemcitabine+vinorelbine→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th- line treatment with carboplatin(AUC6, day 1)+paclitaxe(l 200mg/m2, day 1)(Q3W)was administered in March, 2010...
March 2012: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Yoshiyuki Owada, Kazuyuki Okada, Chikara Ebisui, Syunichirou Makino, Ryo Kato, Takahiko Nishigaki, Masahiro Murakami, Tetsu Yanagisawa, Syu Okamura, Kohei Murata, Hideoki Yokouchi, Masakatsu Kinuta
We report a case of Stage IV inoperable gastric cancer demonstrating a cCR treated with S-1/PTX. The patient was a 65-year-old female with advanced gastric cancer. CT scan suggested an invasion of tumor into a pancreatic body, jejunum and transverse colon. Staging laparoscopy showed it to be positive with peritoneal washing cytology and peritoneal dissemination. The surgical findings were T4a (SE) N2M1H0P1CY1, Stage IV. Chemotherapy was conducted with a combination of S-1/CDDP. After 2 courses of this regimen, the endoscopy findings did not show an improvement, so we decided to change the chemotherapy to S-1/PTX as second-line treatment...
November 2011: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Yukiko Hara, Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, Shuhei Suzuki, Masahiko Shibata, Ryouichi Tomita, Kyoko Matsumoto, Katsuhisa Enomoto, Sadao Amano
We report a case of non-palpating breast cancer with huge lymph node metastasis. The patient was a 58-year-old woman who had a huge tumor at her right armpit. The tumor was 4 cm in diameter. Aspiration biopsy cytology for the tumor was performed. The diagnosis is Class V. Mammography showed an ill-defined mass at her right breast. Ultrasonography revealed a low echoic mass at the C area of her right breast. A core needle biopsy for the breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesterone receptor, and negative for HER2/neu protein expression...
November 2011: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Amal Ahmed-Fouad Halim, Hanan Ahmed Wahba, Hend Ahmed El-Hadaad, Ahmed Abo-Elyazeed
The objective of this study was to compare concomitant chemoradiotherapy based on weekly low-dose gemcitabine versus weekly low-dose paclitaxel in locally advanced head and neck squamous cell carcinoma. Previously, untreated patients with locally advanced squamous cell carcinoma of the head and neck were randomly assigned to one of the two concomitant chemoradiation regimens: (1) weekly gemcitabine at a dose of 100 mg/m(2) over 30 min 1-2 h before radiotherapy and (2) weekly paclitaxal at a dose of 20 mg/m(2) over 60 min 4-6 h before radiotherapy...
March 2012: Medical Oncology
Robert Pirker, Martin Filipits
Blockade of the epidermal growth factor receptor (EGFR) by monoclonal antibodies is a strategy to improve outcome in patients with non-small cell lung cancer. Cetuximab, a chimeric anti-EGFR monoclonal antibody, has been studied in combination with different chemotherapy protocols in both phase II and phase III trials in patients with advanced NSCLC. In the phase III FLEX trial, cetuximab added to cisplatin/vinorelbine resulted in an absolute overall survival benefit of 1.2 months compared to the same chemotherapy alone in patients with advanced EGFR-expressing NSCLC...
October 2011: Critical Reviews in Oncology/hematology
Long Li, Hong We, Jing Chen, Yong Zhao
AIM: To Study on the effects of paclitaxel on macrophages derived from the mouse bone marrow cells. METHODS: The bone marrow cells flushed from BALB/c tibia, femur and hipbone were resuspended in RPMI1640 containing M-CSF and seeded in six-well plates. Then they were cultured in RPMI1640 containing M-CSF in the presence or absence of paclitaxel for seven days. The phenotypes and phagocytosis of the macrophages derived from mice bone marrow cells were measured by FCM and their antigen presentation was detected by DTH...
December 2008: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
C Jin, H Wu, J Liu, L Bai, G Guo
BACKGROUND AND OBJECTIVE: The inability of radiotherapy to eradicate completely certain human tumours may be due to the presence of resistant hypoxic cells. Several studies have confirmed the radiosensitizing effect of paclitaxel, a microtubular inhibitor. The object of this study was to evaluate the physicochemical characteristics of paclitaxel-loaded nanoparticles, and determine the ability of the released paclitaxel to radiosensitize hypoxic human breast carcinoma cells (MCF-7) with respect to radiation dose...
February 2007: Journal of Clinical Pharmacy and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"